MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, AMLX had $166,625K increase in cash & cash equivalents over the period. -$30,392K in free cash flow.

Cash Flow Overview

Change in Cash
$166,625K
Free Cash flow
-$30,392K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-34,386 -77,350
Stock-based compensation expense
7,076 14,183
Depreciation expense
120 297
Accretion of investment discounts, net
1,243 3,226
Other non-cash items
0 -264
Accounts receivable, net
30 -345
Interest receivable
55 -73
Prepaid expenses and other current assets
3,221 -6,523
Operating lease right-of-use assets
336 1,099
Other assets
0 -24
Accounts payable
-33 338
Accrued expenses
1,095 -6,484
Inventory impairment and loss on firm purchase commitments
-0
Operating lease liabilities
-27 -1,158
Net cash used in operating activities
-30,368 -65,072
Purchases of property and equipment
24 28
Purchases of investments
58,740 142,637
Proceeds from maturities of marketable securities
64,000 122,000
Net cash (used in) provided by investing activities
5,236 -20,665
Proceeds from financings, net of issuance costs
191,111 65,577
Proceeds from exercise of stock options and rsus vesting
2,659 1,042
Withholding taxes paid on stock-based awards
2,164 988
Net cash provided by financing activities
191,606 65,631
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents
151 805
Net increase (decrease) in cash, cash equivalents and restricted cash equivalents
166,625 -19,301
Cash and cash equivalents at beginning of period
78,837 -
Cash and cash equivalents at end of period
226,161 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals, Inc. (AMLX)